眼科領域における遺伝子治療市場 - 市場の洞察、疫学、市場予測：2034年

主要7ヶ国の眼科領域における遺伝子治療の総市場規模は、2020年にはほぼ5,000万米ドルとなりました。同市場は、予測期間中（2024年～2034年）にさらに成長すると予測されています。

眼科領域における遺伝子治療の市場規模が最も大きいのは米国で、2020年には約3,500万米ドルであり、2034年までに大きく成長すると予測されています。EU4ヶ国と英国の中では、ドイツが2020年に約600万米ドルと最大の売上シェアを占め、2034年までに大きく成長すると予測されています。

現在、眼科領域で承認されている遺伝子治療はLUXTURNAのみであり、米国FDAでは2017年12月に、EUでは2018年11月に承認されています。2020年の主要7ヶ国全体の適応症別有病者数では、糖尿病性網膜症が最も多く、次いでウェットAMD、最も少なかったのはレーバー遺伝性視神経症でした。主要7ヶ国全体の適応症別症例数では、2020年に最も症例数が少ないのは「色覚異常」です。

遺伝子治療は、遺伝子の変化など疾患の根本的な原因に対処することを目的としています。遺伝子治療とは、病気の治療や予防のために遺伝物質を使用することです。DNAやRNAといった遺伝物質には、細胞内で生成されるタンパク質（またはタンパク質群）を変化させる命令が含まれています。疾患によっては、細胞内で生成される必須タンパク質が多すぎたり、不十分であったり、あるいは間違っていたりする場合に、そのような変化をもたらすことになります。眼科領域では、乾性加齢黄斑変性症、湿性加齢黄斑変性症、スターガルト病、網膜色素変性症、レーバー先天性黒内障（LCA）など、多くの疾患に対して遺伝子治療が研究されています。

当レポートでは、眼科領域における遺伝子治療市場について調査し、現在の治療法、新薬、個々の治療法の市場シェア、2020年～2034年までの主要7ヶ国の眼科領域における遺伝子治療市場規模の現状と予測を提供します。また、眼科領域における遺伝子治療の現在の治療法/アルゴリズム、アンメットメディカルニーズを網羅し、最良の機会を発掘し、市場の潜在力を評価します。

目次

第1章 主要な洞察

第2章 レポートのイントロダクション

第3章 眼科領域における遺伝子治療のエグゼクティブサマリー

第4章 主要な出来事

第5章 疫学と市場予測調査手法

第6章 主要7ヶ国における眼科市場概要

• 2025年の治療法別市場シェア（%）分布
• 2032年の治療法別市場シェア（%）分布

第7章 病気の背景と概要

• 遺伝子治療
• 眼科領域における遺伝子治療
• 遺伝子治療に伴うリスク
• 遺伝子治療における課題

第8章 疫学と患者人口

• 主な調査結果
• 仮定と根拠：主要7ヶ国
• 主要7ヶ国における疫学シナリオ

第9章 上市済み薬剤

第10章 新興治療法

第11章 遺伝子治療眼科：主要7ヶ国分析

• 主な調査結果
• 市場の見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7ヶ国の眼科領域における遺伝子治療の市場規模
• 主要7ヶ国の眼科領域における遺伝子治療の市場規模、適応別
• 主要7ヶ国の眼科領域における遺伝子治療の市場規模、治療法別
• 米国の市場規模
• EU4ヶ国と英国の市場規模
• 日本の市場規模

第12章 アンメットニーズ

第13章 SWOT分析

第14章 コルの見解

第15章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本
• 眼科領域における遺伝子治療の市場アクセスと償還

第16章 付録

第17章 DEVEINSIGHTの機能

第18章 免責事項

第19章 DELVEINSIGHTについて

List of Tables

• Table 1: Summary of Gene Therapies in Ophthalmology Market and Epidemiology (2020-2034)
• Table 2: List of sources Used for Epidemiology Evaluation for shortlisted Indication
• Table 3: Total Diagnosed Prevalent Cases of Selected Indications in the 7MM (thousands) (2020-2034)
• Table 4: Indication-wise Eligible Cases in the 7MM (thousands) (2020-2034)
• Table 5: Indication-wise Treated Cases in the 7MM (thousands) (2020-2034)
• Table 6: LUXTURNA, Clinical Trial Description, 2024
• Table 7: Comparison of Emerging Drugs Under Development
• Table 8: Clinical Trials Description: Botaretigene sparoparvovec
• Table 9: Clinical Trials Description: AGTC-501
• Table 10: Clinical Trials Description: MCO-010
• Table 11: Clinical Trials Description: GS030
• Table 12: Clinical Trials Description: 4D 125
• Table 13: Clinical Trials Description: CTx PDE6B
• Table 14: Clinical Trials Description: OCU 400
• Table 15: Clinical Trials Description: BS01
• Table 16: Clinical Trials Description: LUMEVOQ
• Table 17: Clinical Trials Description: NFS-01
• Table 18: Clinical Trials Description: ADVM-022
• Table 19: Clinical Trials Description: JNJ-1887 (AAVCAGsCD59/JNJ-81201887)
• Table 20: Clinical Trials Description: EYS 606
• Table 21: Clinical Trials Description: 4D 150
• Table 22: Clinical Trials Description: EXG102-031
• Table 23: Clinical Trials Description: AAV RPE65
• Table 24: Clinical Trials Description: AAV-CNGB3
• Table 25: Clinical Trials Description: AAVCNGA3
• Table 26: Clinical Trials Description: NFS-02
• Table 27: Clinical Trials Description: 4D 110
• Table 28: Clinical Trials Description: ATSN-101
• Table 29: Clinical Trials Description: ATSN-201
• Table 30: Clinical Trials Description: OCU 410
• Table 31: Clinical Trials Description: OCU410ST
• Table 32: Clinical Trials Description: AGTC-402
• Table 33: Clinical Trials Description: AGTC-401
• Table 34: Clinical Trials Description: ABBV-RGX-314
• Table 35: Clinical Trials Description: SKG0106
• Table 36: Clinical Trials Description: HG004
• Table 37: Clinical Trials Description: OPGx-001
• Table 38: LUXTURNA: Journey to approval
• Table 39: Key Market Forecast Assumption of Gene Therapies in Ophthalmology in the United States
• Table 40: Key Market Forecast Assumption of Gene Therapies in Ophthalmology in EU4 and the UK
• Table 41: Key Market Forecast Assumption of Gene Therapies in Ophthalmology in Japan
• Table 42: Market Size of Gene Therapies in Ophthalmology in the 7MM, USD million (2020-2034)
• Table 43: Indication-wise Market Size of Gene Therapies in Ophthalmology in the 7MM, USD million (2020-2034)
• Table 44: Market Size of Gene Therapies in Ophthalmology by Therapies in the 7MM, USD million (2020-2034)
• Table 45: Market Size of Gene Therapies in Ophthalmology by Therapies in the US, USD million (2020-2034)
• Table 46: Market Size of Gene Therapies in Ophthalmology by Therapies in the US, USD million (2020-2034)
• Table 47: Indication-wise Market size of Gene Therapies in Ophthalmology in Germany, USD million (2020-2034)
• Table 48: Indication-wise Market size of Gene Therapies in Ophthalmology in France, USD million (2020-2034)
• Table 49: Indication-wise Market size of Gene Therapies in Ophthalmology in Italy, USD million (2020-2034)
• Table 50: Indication-wise Market size of Gene Therapies in Ophthalmology in Spain, USD million (2020-2034)
• Table 51: Indication-wise Market size of Gene Therapies in Ophthalmology in the UK, USD million (2020-2034)
• Table 52: Indication-wise Market size of Gene Therapies in Ophthalmology in EU4 and the UK, USD million (2020-2034)
• Table 53: Market Size of Gene Therapies in Ophthalmology by Therapies in Germany, USD million (2020-2034)
• Table 54: Market Size of Gene Therapies in Ophthalmology by Therapies in France, USD million (2020-2034)
• Table 55: Market Size of Gene Therapies in Ophthalmology by Therapies in Italy, USD million (2020-2034)
• Table 56: Market Size of Gene Therapies in Ophthalmology by Therapies in Spain, USD million (2020-2034)
• Table 57: Market Size of Gene Therapies in Ophthalmology by Therapies in the UK, USD million (2020-2034)
• Table 58: Market Size of Gene Therapies in Ophthalmology by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 59: Market Size of Gene Therapies in Ophthalmology by Therapies in Japan, USD million (2020-2034)
• Table 60: Market Size of Gene Therapies in Ophthalmology by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1: Total Diagnosed Prevalent Cases of Selected Indications in the 7MM (2020-2034)
• Figure 2: Indication-wise Eligible Cases in the 7MM (2020-2034)
• Figure 3: Indication-wise Treated Cases in the 7MM (2020-2034)
• Figure 4: Market size of Gene Therapies in Ophthalmology in the 7MM, USD million (2020-2034)
• Figure 5: Indication-wise Market size of Gene Therapies in Ophthalmology in the 7MM, USD million (2020-2034)
• Figure 6: Market Size of Gene Therapies in Ophthalmology in the 7MM, USD million (2020-2034)
• Figure 7: Indication-wise Market size of Gene Therapies in Ophthalmology in the US, USD million (2020-2034)
• Figure 8: Market Size of Gene Therapies in Ophthalmology in the US, USD million (2020-2034)
• Figure 9: Indication-wise Market size of Gene Therapies in Ophthalmology in EU4 and the UK, USD million (2020-2034)
• Figure 10: Market Size of Gene Therapies in Ophthalmology in EU4 and the UK, USD million (2020-2034)
• Figure 11: Indication-wise Market size of Gene Therapies in Ophthalmology in Japan, USD million (2020-2034)
• Figure 12: Market Size of Gene Therapies in Ophthalmology in Japan, USD million (2020-2034)
• Figure 13: Health Technology Assessment
• Figure 14: Reimbursement Process in Germany
• Figure 15: Reimbursement Process in France
• Figure 16: Reimbursement Process in Italy
• Figure 17: Reimbursement Process in Spain
• Figure 18: Reimbursement Process in the United Kingdom
• Figure 19: Reimbursement Process in Japan

Key Highlights:

• Currently, there is only one approved gene therapy in ophthalmology, that is LUXTURNA, which was approved by the US FDA in December 2017, and by the EU in November 2018.
• In 2020, the market size of gene therapy in ophthalmology was highest in the US among the 7MM, accounting for approximately USD 35 million, which is further expected to increase by 2034.
• Among the total prevalent cases of selected indications across the 7MM, the highest number of cases comprised of Diabetic Retinopathy, followed by Wet-AMD, and the lowest number of cases comprised of Leber Hereditary Optic Neuropathy in 2020.
• Among the indication-wise treated cases across the 7MM, the lowest number of cases comprised of Achromatopsia in 2020.
• In December 2023, the US FDA granted the RMAT designation, and in October 2023, the EMA granted PRIME designation to 4D-150 for intravitreal treatment of wet AMD.
• 4D Molecular Therapeutics is anticipating a Phase II dose expansion interim landmark data analysis of the PRISM study of 4D-150 in wet AMD at the Angiogenesis, Exudation, and Degeneration 2024 Conference and an update on the US FDA feedback on Phase III pivotal trial plan in February 2024.
• In December 2023, Ocugen announced that the US FDA had granted RMAT designation to OCU400 for the treatment of retinitis pigmentosa associated with RHO mutations.

DelveInsight's "Gene Therapy in Ophthalmology-Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the Gene Therapy in Ophthalmology, historical and forecasted epidemiology as well as the Gene Therapy in Ophthalmology market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Gene Therapy in Ophthalmology market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Gene Therapy in Ophthalmology market size from 2020 to 2034. The report also covers current Gene Therapy in Ophthalmology treatment practices/algorithms, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Gene Therapy in Ophthalmology Understanding

Gene Therapy in Ophthalmology Overview

Gene therapy aims to address the underlying cause of disease, such as changes in genes. Gene therapy is the use of genetic material to treat or prevent disease. The genetic material that is delivered, DNA or RNA, has instructions to change how a protein-or group of proteins-is produced by the cell. For some diseases, this means making changes to account for too much, insufficient, or incorrect essential proteins produced within cells. Gene therapy is being investigated in ophthalmology for a number of diseases, including dry age-related macular degeneration, wet age-related macular degeneration, Stargardt disease, retinitis pigmentosa, Leber's Congenital Amaurosis (LCA), and others.

Further details are provided in the report…

Gene Therapy in Ophthalmology Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Selected Indications for Gene Therapies in Ophthalmology in the 7MM, Indication-wise Eligible Cases in the 7MM, and Indication-wise Treated Cases in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• Among all the diagnosed prevalent cases of selected indications for gene therapies in ophthalmology, the highest cases comprised of Diabetic Retinopathy, with approximately 9,200,000 cases in the 7MM in 2020.
• In the US, the highest number of diagnosed prevalent cases comprised of Diabetic Retinopathy with approximately 4,800,000, while the lowest cases comprised of Leber Hereditary Optic Neuropathy in 2020.
• In EU4 and the UK, Germany accounted for the highest number of Retinitis Pigmentosa treated cases with approximately 24,000 in 2020.
• In Japan, the total number of wet-AMD eligible cases was approximately 800,000 in 2020.

Gene Therapy in Ophthalmology Drug Chapters

The drug chapter segment of the gene therapy in ophthalmology report encloses a detailed analysis of gene therapy in ophthalmology emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand gene therapy in ophthalmology clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

LUXTURNA is an AAV vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells, as determined by the treating physician. Mutations in the RPE65 (retinal pigment epithelial 65 kDa protein) gene lead to reduced or absent levels of RPE65 isomerohydrolase activity, blocking the visual cycle and resulting in impairment of vision. Injection of LUXTURNA into the subretinal space results in the transduction of some retinal pigment epithelial cells with a cDNA encoding normal human RPE65 protein, thus providing the potential to restore the visual cycle. It was approved by the US FDA in December 2017, and by the European Commission in November 2018.

Emerging Drugs

RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF. ATMOSPHERE, the first of two planned pivotal trials for the evaluation of subretinal delivery of RGX-314 in patients with wet AMD, is active and enrolling patients. In May 2023 the company announced the transfer of the IND applications to AbbVie for all ongoing clinical trials and the expansion of the ATMOSPHERE and ASCENT pivotal trials of RGX-314 delivered subretinally for the treatment of patients with wet AMD to support new global registration plans. The new global site plans and expanded enrollment targets are expected to support regulatory submissions of ABBV-RGX-314 with the US FDA and the EMA in late 2025 through the first half of 2026.

GS010: GenSight Biologics

GS010 targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, which allows the platform to specifically address defects inside the mitochondria using an AAV vector. The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. Currently, the drug is in the Phase III stage of its development for the treatment of LHON.

NFS-01: Neurophth Therapeutics

NFS-01 (NR082, rAAV2-ND4), a novel recombinant adeno-associated viral vector, serotype 2, containing a mitochondria codon-optimized NADH-dehydrogenase subunit 4 (ND4) gene under the control of the cytomegalovirus promoter and enhancer, is a novel gene therapy product that is being developed for the treatment of LHON associated with mtND4 mutations. NR082 can deliver the correct genes to the patient's damaged optic ganglion cells through intravitreal injection, thus repairing the mitochondrial biological respiratory chain, and restoring the vitality and visual function of optic ganglion cells. Currently, the drug is in the Phase II/III stage of its development for the treatment of Leber's hereditary optic atrophy.

Note: Detailed therapies assessment will be provided in the final report.

Gene Therapy in Ophthalmology Market Outlook

The gene therapy field experienced ups and downs between 1989 and 2012. After two decades of dashed expectations, the first gene therapy was approved in the EU in 2012. This likely boosted this field, and the development of gene therapies increased prominently. Gene therapies are considered very promising to treat many chronic and disabling previously untreatable diseases. Manufacturers are investing more in this field, and an increasing number of products are under clinical development, mostly in the early stages. In December 2017, Spark Therapeutics announced that their drug candidate LUXTURNA received US FDA approval for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. LUXTURNA is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease, and the first AAV vector gene therapy approved in the United States. After the approval era of LUXTURNA, many companies entered into the gene therapy in the ophthalmology space and target many genes that cause many diseases such as Retinitis Pigmentosa, LCA, LHON, Achromatopsia, Choroideremia, AMD (wet-AMD and dry-AMD), Diabetic Retinopathy, DME, and others. In the Retinitis Pigmentosa pipeline among the emerging candidates, Beacon's AGTC-501 aims to restore RPGR gene function in patients with X-linked retinitis pigmentosa. In December 2023, Beacon presented unmasked three-month data from its randomized, controlled, multicenter Phase II SKYLINE trial of AGTC-501 in patients with X-linked retinitis pigmentosa at the FLORetina ICOOR 2023. The landscape for Diabetic Retinopathy and DME therapeutic development is currently limited, with only a few noteworthy players such as AbbVie/REGENXBIO's ABBV-RGX-314 and 4D Molecular Therapeutics (4D-150).

Overall, the gene therapy in the ophthalmology market is further expected to increase in the forecast period (2024-2034).

• The total market size of gene therapy in ophthalmology in the 7MM was nearly USD 50 million in 2020 and is projected to grow during the forecast period (2024-2034).
• According to the estimates, the highest market size of gene therapy in ophthalmology is from the United States, that is around USD 35 million, in 2020 and is anticipated to grow significantly by 2034.
• Among EU4 and the UK, Germany had the maximum revenue share in 2020, that is around USD 6 million, and is expected to grow significantly by 2034.

Gene Therapy in Ophthalmology Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to be launched in the market during the study period 2020-2034. The analysis covers Gene Therapy in Ophthalmology market uptake by drugs; patient uptake by therapies; and sales of each drug.

Gene Therapy in Ophthalmology Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition and merger, licensing, and patent details for Gene Therapy in Ophthalmology emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and 'SME's opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on gene therapy in ophthalmology's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as Pharmaceutical Research and Manufacturers of America and other organizations. Their opinion helps understand and validate current and emerging therapies or market trends in gene therapy in ophthalmology. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

The reimbursement landscape for gene therapies in ophthalmology, exemplified by treatments like LUXTURNA for inherited retinal dystrophies, is characterized by intricacies and variations across different countries. With high initial costs associated with the development and manufacturing of gene therapies, reimbursement models often adopt a value-based approach, considering the long-term benefits and potential cost savings compared to traditional treatments. Health Technology Assessments (HTAs) are commonly employed to evaluate clinical effectiveness, cost-effectiveness, and overall value, taking into account factors like disease severity and the availability of alternative treatments. The American healthcare system is highly fragmented, with various public and private health insurers. This makes for a more complex environment than in European countries, where there tends to be a single, national health insurance system that undertakes HTAs and decides how reimbursement and patient access are managed. Thus, in the US, various organizations decide which treatments to provide health insurance coverage for and under what conditions. In January 2018, Spark Therapeutics announced three new payer programs: an outcomes-based rebate arrangement with a long-term durability measure, an innovative contracting model, and a proposal to CMS under which payments for LUXTURNA would be made over time.

Note: Detailed assessment will be provided in the final report.

Scope of the Report:

• The report covers a descriptive overview of gene therapy in ophthalmology, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into gene therapy in ophthalmology epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for gene therapy in ophthalmology is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the gene therapy in ophthalmology market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM gene therapy in ophthalmology market.

Gene Therapy in Ophthalmology Report Insights

Gene Therapy in Ophthalmology Report Insights

• Patient Population
• Therapeutic Approaches
• Gene Therapy in Ophthalmology Pipeline Analysis
• Gene Therapy in Ophthalmology Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Gene Therapy in Ophthalmology Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Gene Therapy in Ophthalmology Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Gene Therapy in Ophthalmology Report Assessment

• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What was the gene therapy in ophthalmology market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the gene therapy in ophthalmology total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM and which country will have the largest gene therapy in ophthalmology market size during the study period (2020-2034)?
• At what CAGR, the gene therapy in the ophthalmology market is expected to grow at the 7MM level during the study period (2020-2034)?
• What would be the gene therapy in the ophthalmology market outlook across the 7MM during the study period (2020-2034)?
• What would be the gene therapy in ophthalmology market growth till 2034 and what will be the resultant market size in the year 2034?
• What are the disease risk, burden, and unmet needs of gene therapy in ophthalmology?
• What is the historical gene therapy in the ophthalmology patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What would be the forecasted patient pool of gene therapy in ophthalmology at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population about gene therapy in ophthalmology?
• At what CAGR the population is expected to grow across the 7MM during the study period (2020-2034)?
• How many companies are developing therapies for gene therapy in ophthalmology?
• How many emerging therapies are in the mid-stage and late stage of development for gene therapy in ophthalmology?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the gene therapy in ophthalmology?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for gene therapy in ophthalmology and their status?
• What are the key designations that have been granted for gene therapies in ophthalmology?
• What are the 7MM historical and forecasted market of gene therapy in ophthalmology?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the gene therapy in ophthalmology.
• To understand the future market competition in the gene therapy in ophthalmology market and an Insightful review of the SWOT analysis of gene therapy in ophthalmology.
• Organize sales and marketing efforts by identifying the best opportunities for gene therapy in ophthalmology in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the gene therapy in ophthalmology market.
• To understand the future market competition in the gene therapy in ophthalmology market.

Table of Contents

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY OF GENE THERAPIES IN OPHTHALMOLOGY

4. KEY EVENTS

5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6. GENE THERAPIES IN OPHTHALMOLOGY MARKET OVERVIEW AT A GLANCE IN THE 7MM

• 6.1. MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2025
• 6.2. MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN 2032

7. DISEASE BACKGROUND AND OVERVIEW

• 7.1. GENE THERAPY
  • 7.1.1. Types of Gene Therapy
  • 7.1.2. How Does Gene Therapy Work?
  • 7.1.3. Vectors in Gene Therapy
    • 7.1.3.1. Adeno-associated viral (AAV) vectors
    • 7.1.3.2. Adenoviral vectors
    • 7.1.3.3. Lentiviral and retroviral vectors
  • 7.1.4. Limitations of Vectors
• 7.2. GENE THERAPIES IN OPHTHALMOLOGY
• 7.3. RISKS ASSOCIATED WITH GENE THERAPY
• 7.4. CHALLENGES IN GENE THERAPIES

8. EPIDEMIOLOGY AND PATIENT POPULATION

• 8.1. KEY FINDINGS
• 8.2. ASSUMPTIONS AND RATIONALE: 7MM
• 8.3. EPIDEMIOLOGY SCENARIO IN THE 7MM
  • 8.3.1. Total Diagnosed Prevalent Cases of Selected Indications in the 7MM
  • 8.3.2. Indication-wise Eligible Cases in the 7MM
  • 8.3.3. Indication-wise Treated Cases in the 7MM

9. MARKETED DRUGS

• 9.1. LUXTURNA: SPARKS THERAPEUTICS (ROCHE)/NOVARTIS
  • 9.1.1. Product Description
  • 9.1.2. Regulatory Milestones
  • 9.1.3. Others Developmental Activities
  • 9.1.4. Clinical Developmental Activities
    • 9.1.4.1. Clinical Trial Information
  • 9.1.5. Safety and Efficacy
  • 9.1.6. Product Profile

10. EMERGING THERAPIES

• 10.1. KEY COMPETITORS
• 10.2. BOTARETIGENE SPAROPARVOVEC: JOHNSON & JOHNSON INNOVATIVE MEDICINE /MEIRAGTX
  • 10.2.1. Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3. Clinical Developmental Activities
  • 10.2.4. Safety and Efficacy
• 10.3. AGTC-501: BEACON THERAPEUTICS
  • 10.3.1. Product Description
  • 10.3.2. Other Development Activities
  • 10.3.3. Clinical Developmental Activities
  • 10.3.4. Safety and Efficacy
• 10.4. MCO-010: NANOSCOPE THERAPEUTICS
  • 10.4.1. Product Description
  • 10.4.2. Other Developmental Activities
  • 10.4.3. Clinical Developmental Activities
  • 10.4.4. Safety and Efficacy
• 10.5. GS030: GENSIGHT BIOLOGICS
  • 10.5.1. Product Description
  • 10.5.2. Other Developmental Activities
  • 10.5.3. Clinical Developmental Activities
  • 10.5.4. Safety and Efficacy
• 10.6. 4D 125: 4D MOLECULAR THERAPEUTICS
  • 10.6.1. Product Description
  • 10.6.2. Other Developmental Activities
  • 10.6.3. Clinical Developmental Activities
  • 10.6.4. Safety and Efficacy
• 10.7. CTX PDE6B: COAVE THERAPEUTICS
  • 10.7.1. Product Description
  • 10.7.2. Other Developmental Activities
  • 10.7.3. Clinical Developmental Activities
  • 10.7.4. Safety and Efficacy
• 10.8. OCU 400: OCUGEN
  • 10.8.1. Product Description
  • 10.8.2. Other Developmental Activities
  • 10.8.3. Clinical Developmental Activities
  • 10.8.4. Safety and Efficacy
• 10.9. BS01: BIONIC SIGHT
  • 10.9.1. Product Description
  • 10.9.2. Clinical Developmental Activities
  • 10.9.3. Safety and Efficacy
• 10.1. LUMEVOQ: GENSIGHT BIOLOGICS
  • 10.10.1. Product Description
  • 10.10.2. Other Developmental Activities
  • 10.10.3. Clinical Development Activities
  • 10.10.4. Safety and Efficacy
• 10.11. NR082 (NFS-01): NEUROPHTH THERAPEUTICS
  • 10.11.1. Product Description
  • 10.11.2. Other Development Activities
  • 10.11.3. Clinical Development Activities
  • 10.11.4. Safety and Efficacy
• 10.12. ADVM-022 (AAV.7M8-AFLIBERCEPT): ADVERUM BIOTECHNOLOGIES
  • 10.12.1. Product Description
  • 10.12.2. Product Developmental Activities
  • 10.12.3. Clinical Development Activities
  • 10.12.4. Safety and Efficacy
• 10.13. JNJ-1887 (AAVCAGSCD59/JNJ-81201887): JOHNSON & JOHNSON INNOVATIVE MEDICINE
  • 10.13.1. Product Description
  • 10.13.2. Other Developmental Activities
  • 10.13.3. Clinical Development Activities
  • 10.13.4. Safety and Efficacy
• 10.14. EYS 606: EYEVENSYS
  • 10.14.1. Product Description
  • 10.14.2. Other Developmental Activities
  • 10.14.3. Clinical Development Activities
  • 10.14.4. Safety and Efficacy
• 10.15. 4D 150: 4D MOLECULAR THERAPEUTICS
  • 10.15.1. Product Description
  • 10.15.2. Other Developmental Activities
  • 10.15.3. Clinical Development Activities
• 10.16. EXG102-031: EXEGENESIS BIO
  • 10.16.1. Product Description
  • 10.16.2. Other Developmental Activities
  • 10.16.3. Clinical Development Activities
  • 10.16.4. Safety and Efficacy
• 10.17. AAV-RPE65: MEIRAGTX/JOHNSON & JOHNSON INNOVATIVE MEDICINE
  • 10.17.1. Product Description
  • 10.17.2. Other Developmental Activities
  • 10.17.3. Clinical Development Activities
  • 10.17.4. Safety and Efficacy
• 10.18. AAV-CNGB3: MEIRAGTX/JOHNSON & JOHNSON INNOVATIVE MEDICINE
  • 10.18.1. Product Description
  • 10.18.2. Other Developmental Activities
  • 10.18.3. Clinical Development Activities
  • 10.18.4. Safety and Efficacy
• 10.19. AAV-CNGA3: MEIRAGTX/JOHNSON & JOHNSON INNOVATIVE MEDICINE
  • 10.19.1. Product Description
  • 10.19.2. Other Developmental Activities
  • 10.19.3. Clinical Development Activities
  • 10.19.4. Safety and Efficacy
• 10.2. NFS-02: NEUROPHTH THERAPEUTICS
  • 10.20.1. Product Description
  • 10.20.2. Other Developmental Activities
  • 10.20.3. Clinical Development Activities
  • 10.20.4. Safety and Efficacy
• 10.21. 4D 110: 4D MOLECULAR THERAPEUTICS
  • 10.21.1. Product Description
  • 10.21.2. Other Developmental Activities
  • 10.21.3. Clinical Development Activities
  • 10.21.4. Safety and Efficacy
• 10.22. ATSN-101: ATSENA THERAPEUTICS
  • 10.22.1. Product Description
  • 10.22.2. Other Developmental Activities
  • 10.22.3. Clinical Developmental Activities
  • 10.22.4. Safety and Efficacy
• 10.23. ATSN-201: ATSENA THERAPEUTICS
  • 10.23.1. Product Description
  • 1.1.1. Other Developmental Activities
  • 10.23.2. Clinical Developmental Activities
• 10.24. OCU410: OCUGEN
  • 10.24.1. Product Description
  • 10.24.2. Clinical Developmental Activities
  • 10.24.3. Safety and Efficacy
• 10.25. OCU410ST: OCUGEN
  • 10.25.1. Product Description
  • 1.1.2. Other Developmental Activities
  • 10.25.2. Clinical Developmental Activities
• 10.26. AGTC-402: BEACON THERAPEUTICS
  • 10.26.1. Product Description
  • 1.1.3. Other Developmental Activities
  • 10.26.2. Clinical Developmental Activities
  • 10.26.3. Safety and Efficacy
• 10.27. AGTC-401: BEACON THERAPEUTICS
  • 10.27.1. Product Description
  • 1.1.4. Other Developmental Activities
  • 10.27.2. Clinical Developmental Activities
  • 10.27.3. Safety and Efficacy
• 10.28. ABBV-RGX-314: ABBVIE/REGENXBIO
  • 10.28.1. Product Description
  • 10.28.2. Other Developmental Activities
  • 10.28.3. Clinical Developmental Activities
  • 10.28.4. Safety and Efficacy
• 10.29. SKG0106: SKYLINE THERAPEUTICS
  • 10.29.1. Product Description
  • 10.29.2. Other Developmental Activities
  • 10.29.3. Clinical Developmental Activities
  • 10.29.4. Safety and Efficacy
• 10.3. HG 004: HUIDAGENE THERAPEUTICS
  • 10.30.1. Product Description
  • 10.30.2. Other Developmental Activities
  • 10.30.3. Clinical Developmental Activities
• 10.31. OPGX-001: OPUS GENETICS
  • 10.31.1. Product Description
  • 10.31.2. Other Developmental Activities
  • 10.31.3. Clinical Developmental Activities
  • 10.31.4. Safety and Efficacy

11. GENE THERAPIES OPHTHALMOLOGY: 7MM ANALYSIS

• 11.1. KEY FINDINGS
• 11.2. MARKET OUTLOOK
• 11.3. CONJOINT ANALYSIS
• 11.4. KEY MARKET FORECAST ASSUMPTIONS
• 11.5. MARKET SIZE OF GENE THERAPIES IN OPHTHALMOLOGY IN THE 7MM
• 11.6. INDICATION-WISE MARKET SIZE OF GENE THERAPIES IN OPHTHALMOLOGY IN THE 7MM
• 11.7. MARKET SIZE OF GENE THERAPIES IN OPHTHALMOLOGY BY THERAPIES IN THE 7MM
• 11.8. UNITED STATES MARKET SIZE
  • 11.8.1. Indication-wise Market Size of Gene Therapies in Ophthalmology in the United States
  • 11.8.2. Market Size of Gene Therapies in Ophthalmology by Therapies in the United States
• 11.9. EU4 AND THE UK MARKET SIZE
  • 11.9.1. Indication wise Market Size of Gene Therapies in Ophthalmology in EU4 and the UK
  • 11.9.2. Market Size of Gene Therapies in Ophthalmology by Therapies in EU4 and the UK
• 11.1. JAPAN MARKET SIZE
  • 11.10.1. Indication-wise Market Size of Gene Therapies in Ophthalmology in Japan
  • 11.10.2. Market Size of Gene Therapies in Ophthalmology by Therapies in Japan

12. UNMET NEEDS

13. SWOT ANALYSIS

14. KOL VIEWS

15. MARKET ACCESS AND REIMBURSEMENT

• 15.1. UNITED STATES
  • 15.1.1. Centre for Medicare and Medicaid Services (CMS)
• 15.2. EU4 AND THE UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. JAPAN
  • 15.3.1. MHLW
• 15.4. MARKET ACCESS AND REIMBURSEMENT OF GENE THERAPIES IN OPHTHALMOLOGY

16. APPENDIX

• 16.1. BIBLIOGRAPHY
• 16.2. REPORT METHODOLOGY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT